Company
Home
About Us
Message from the CEO
Leadership Team
News
Statistics
Incidence of Medical Errors
Corporate Responsibility
Quality Compliance
Terms of Use
Syringes
Safe-T-Syringe
®
Dose-2-Weight Syringe – OTC Pediatrics
Dose-2-Weight Syringe – Rx Pediatrics
Diluent-2-Dose™
Vi-Syringe™
Combinatorial Kits
Calibrated Drug Delivery™
Pedia-Dose
®
Safe-T-Dose
®
Vi-Injection Kit™
Self Injection
Momenta-Dose™ Overview
Momenta-Dose™ PFS
Infusion Devices
Safe-T-Fuse™
Safe-T-Fuse™ Home Therapy
Safe-2-Dose® Containers
Inquiries
Contact Us
Sales Inquiries
Partnering with Asepsis
Leadership Team
asepsismedical
>
Leadership Team
Recent News
Asepsis Announces the Grant of U.S. Patent 10,857,299 for the Multi-Dose Safe-2-Dose® Syringe platform.
-
Asepsis Announces Australian Patent Acceptance No. 2018232988 for its Multi-Indicia Infants’ and Children’s Oral Medication Dosing Applicator Comprising a Medication Paired Keyed End.
-
Asepsis announces an additional U.S. Patent Grant, US 10,143,622 for its Safe-T-Fuse™ specialty drug infusion system.
-
Asepsis Announces the Grant of Canada Patent Application CA2937327 for the Momenta-Dose™ – Force Actuated Injection.
-
Asepsis announces Notice of Australian Patent Grant 2015209535 for its Momenta-Dose™ – Force Actuated Injection.
-
Tweets by PedNursing
Menu
Company
Home
About Us
Message from the CEO
Leadership Team
News
Statistics
Incidence of Medical Errors
Corporate Responsibility
Quality Compliance
Terms of Use
Syringes
Safe-T-Syringe
®
Dose-2-Weight Syringe – OTC Pediatrics
Dose-2-Weight Syringe – Rx Pediatrics
Diluent-2-Dose™
Vi-Syringe™
Combinatorial Kits
Calibrated Drug Delivery™
Pedia-Dose
®
Safe-T-Dose
®
Vi-Injection Kit™
Self Injection
Momenta-Dose™ Overview
Momenta-Dose™ PFS
Infusion Devices
Safe-T-Fuse™
Safe-T-Fuse™ Home Therapy
Safe-2-Dose® Containers
Inquiries
Contact Us
Sales Inquiries
Partnering with Asepsis